Loading
A phase 3 trial of Fianlimab, Cemiplimab, Nivolumab in melanoma, run by Regeneron Pharmaceuticals, now recruiting.
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) is a phase 3 interventional study registered as NCT06246916 by Regeneron Pharmaceuticals, with 560 participants planned, started 2024-09-09 and due to reach its primary completion in 2027-03-22. Interventions recorded: fianlimab, cemiplimab, relatlimab+nivolumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Shares Fianlimab, Regeneron, Cemiplimab, Melanoma.
Shares Fianlimab, Regeneron, Cemiplimab, Melanoma.
Shares Relatlimab + nivolumab, Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Relatlimab + nivolumab, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Melanoma, Immune checkpoint inhibitors.